Xylometazoline WZF 0.05% nasal drops, solution. 0.5 mg/ml 10 ml x 1

How to use: Use as directed by your doctor
Detailed instructions for use can be found in the leaflet included in the package.

Storage: Store at ambient temperature

Xylometazoline

Polfa Warszawa S.A.

Polfa Warszawa S.A.,
street Karolkowa 22/24,
01-207 Warszawa,
EN

Xylometazolin WZF 0.05% is intended for children from 2 years of age. Should not be used in younger children. Young children may experience agitation or difficulty sleeping. If such symptoms occur, discontinue use of the product. Xylometazolin WZF 0.05%, like other sympathomimetics, should be administered with particular caution to patients with hypersensitivity to adrenomimetic substances, manifested by insomnia, dizziness, tremor,heart rhythm disturbances and increased blood pressure. Patients with long QT syndrome treated with xylometazoline may be at increased risk of severe ventricular arrhythmias. The product should not be used in patients with chronic or vasomotor rhinitis as they tend to use it for longer than 5 days. Using the product for a longer period than recommended may lead to secondary vasodilation and, consequently, to secondary drug-induced rhinitis medicamentosa. The cause of this condition is most likely the inhibition of norepinephrine release from nerve endings by stimulation of presynaptic α-2 receptors. Use with caution in patients with hypertension, angina pectoris and other cardiovascular diseases, diabetes, angle-closure glaucoma, prostatic hyperplasia, and hyperthyroidism. Doses higher than recommended should not be used, especially in children and the elderly. Xylometazolin WZF 0.05% should not be administered during treatment with monoamine oxidase inhibitors and tricyclic antidepressants. The product contains 0.1 mg of benzalkonium chloride in each ml of solution. Benzalkonium chloride may cause irritation or swelling of the nasal mucosa, especially if used for a long time.